论文部分内容阅读
目的探讨新辅助化疗用于晚期卵巢癌的临床效果。方法 2005年1月至2008年10月收治的Ⅲ、Ⅳ期卵巢癌98例,分为先期手术组50例,新辅助化疗组48例,观察临床效果。结果两组病例平均腹水量、平均总瘤灶直径、平均转移灶数、满意减瘤率、术中出血量、手术时间、并发症发生率、1年生存率比较差异有统计学意义(P<0.05)。结论新辅助化疗可明显减小患者的原发肿瘤体积,减少转移瘤灶数量,明显减少患者的腹水量,降低手术难度及减少并发症,提高了手术成功率,对晚期卵巢癌的治疗具有重要的价值。
Objective To investigate the clinical effect of neoadjuvant chemotherapy for advanced ovarian cancer. Methods From January 2005 to October 2008, 98 patients with stage Ⅲ and Ⅳ ovarian cancer were divided into two groups: advanced surgery group (50 cases) and neoadjuvant chemotherapy group (48 cases). The clinical effects were observed. Results The average ascites volume, average total tumor diameter, average number of metastases, satisfactory rate of tumor reduction, intraoperative blood loss, operation time, complication rate and 1-year survival rate were significantly different between the two groups (P < 0.05). Conclusion Neoadjuvant chemotherapy can significantly reduce the patient’s primary tumor volume, reduce the number of metastases, significantly reduce the patient’s ascites, reduce the difficulty of surgery and reduce complications, improve the success rate of surgery, the treatment of advanced ovarian cancer is important the value of.